Abstract: The invention provides a novel process, novel process steps and novel intermediates useful in the synthesis of pharmaceutically active compounds, especially renin inhibitors, such as Allskiren. Inter alia, the invention provides a process for the manufacture of a compound of the formula III, wherein R, R1, R2, R3 and PG are as defined in the specification, or a salt thereof. The manufacture comprises (preferably consists of) reacting a compound of the formula I, with a reagent able to transform hydroxy into X where X is for example a leaving group.

Abstract: The present invention provides a novel process, novel process steps and novel intermediates useful in the synthesis of pharmaceutically active compounds, especially renin inhibitors, such as Aliskiren. Inter alia, the invention provides a process for the manufacture of a compound of the formula III, wherein R, R1, R2, R3 and PG are as defined in the specification, or a salt thereof. The manufacture comprises (preferably consists of) reacting a compound of the formula I, with a reagent able to transform hydroxy into X where X is for example a leaving group.

Abstract: Provided is a process for preparing cyclic somatostatin analogues and the linear intermediates used in this process.

Abstract: The present invention relates to processes for preparing peptides and to intermediates involved in such processes, e.g. a process for preparing a compound of formula VIII wherein R12 and R13 are as defined herein.

Abstract: The present invention relates to processes for preparing peptides and to intermediates involved in such processes, e.g. a process for preparing a compound of formula VIII wherein R12 and R13 are as defined herein.

Abstract: The invention related to a novel process, novel process steps and novel intermediates useful in the synthesis of pharmaceutically active compounds, especially renin inhibitors, such as Aliskiren.

Abstract: The present invention relates to processes for preparing peptides and to intermediates involved in such processes, e.g. a process for preparing a compound of formula VIII wherein R12 and R13 are as defined herein.

Abstract: The present invention relates to processes for preparing peptides and to intermediates involved in such processes, e.g. a process for preparing a compound of formula VIII wherein R12 and R13 are as defined herein.

Abstract: Provided is a process for preparing cyclic somatostatin analogues and the linear intermediates used in this process.

Abstract: The present invention relates to processes for preparing peptides and to intermediates involved in such processes, e.g. a process for preparing a compound of formula VIII wherein R12 and R13 are as defined herein.

Abstract: A polylactide in a purified state, which meets the requirements of the colour strengths of reference solutions B2-B9 of the brown colour test of the European Pharmacopoeia, 2nd Edition (1980) part I, Section V, 6.2 and containing one or more metals in cationic form, the metal ion(s) having a concentration of at most 10 ppm. The polylactide is especially suitable for use as microparticles or implants, and contains preferably a hydrophilic drug, like octreotide or a lipophilic drug like bromocriptine.

Abstract: A polylactide in a purified state, which meets the requirements of

Abstract: A polylactide in a purified state, which meets the requirements of the color strengths of reference solutions B2-B9 of the brown color test of the European Pharmacopoeia, 2nd Edition (1980) part I, Section V, 6.2 and containing one or more metals in cationic form, the metal ion(s) having a concentration of at most 10 ppm. The polylactide is especially suitable for use as microparticles or implants, and contains preferably a hydrophilic drug, like octreotide or a lipophilic drug like bromocriptine.

Abstract: The present invention provides a sugar derivative of a biologically active peptide, which derivative has a prolonged duration of action when compared to the non-sugar modified peptide, and contains at least on one of the amino acid units a sugar residue which is attached to an amino group thereof by a coupling other than a direct N-glycosidic bond, and additionally, when it is a condensation product of a carboxyl group containing sugar and a peptide with less than 8 amino acid units, by a coupling other than a direct amide bond.

Abstract: A product of an oligomer derived from glycolic acid and/or lactic acid, the oligomer having a molecular weight of from 500 to 10,000, the free carboxylic acid group of the oligomer being at least partially in the form of an amide with an amino acid or an ester with a sterol may be used as a matrix material for depot forms, containing pharmacologically active agents.